Literature DB >> 27649042

Combined glutamate and glutamine levels in pain-processing brain regions are associated with individual pain sensitivity.

Matthias Zunhammer1, Lauren M Schweizer, Vanessa Witte, Richard E Harris, Ulrike Bingel, Tobias Schmidt-Wilcke.   

Abstract

The relationship between glutamate and γ-aminobutyric acid (GABA) levels in the living human brain and pain sensitivity is unknown. Combined glutamine/glutamate (Glx), as well as GABA levels can be measured in vivo with single-voxel proton magnetic resonance spectroscopy. In this cross-sectional study, we aimed at determining whether Glx and/or GABA levels in pain-related brain regions are associated with individual differences in pain sensitivity. Experimental heat, cold, and mechanical pain thresholds were obtained from 39 healthy, drug-free individuals (25 men) according to the quantitative sensory testing protocol and summarized into 1 composite measure of pain sensitivity. The Glx levels were measured using point-resolved spectroscopy at 3 T, within a network of pain-associated brain regions comprising the insula, the anterior cingulate cortex, the mid-cingulate cortex, the dorsolateral prefrontal cortex, and the thalamus. GABA levels were measured using GABA-edited spectroscopy (Mescher-Garwood point-resolved spectroscopy) within the insula, the anterior cingulate cortex, and the mid-cingulate cortex. Glx and/or GABA levels correlated positively across all brain regions. Gender, weekly alcohol consumption, and depressive symptoms were significantly associated with Glx and/or GABA levels. A linear regression analysis including all these factors indicated that Glx levels pooled across pain-related brain regions were positively associated with pain sensitivity, whereas no appreciable relationship with GABA was found. In sum, we show that the levels of the excitatory neurotransmitter glutamate and its precursor glutamine across pain-related brain regions are positively correlated with individual pain sensitivity. Future studies will have to determine whether our findings also apply to clinical populations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27649042     DOI: 10.1097/j.pain.0000000000000634

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  16 in total

1.  Changes in metabolites in the brain of patients with fibromyalgia after treatment with an NMDA receptor antagonist.

Authors:  Nicolas Fayed; Barbara Oliván; Yolanda Lopez Del Hoyo; Eva Andrés; Mari Cruz Perez-Yus; Alicia Fayed; Luisa F Angel; Antoni Serrano-Blanco; Miquel Roca; Javier Garcia Campayo
Journal:  Neuroradiol J       Date:  2019-06-19

2.  Gi protein functions in thalamic neurons to decrease orofacial nociceptive response.

Authors:  Jennifer Strand; Crystal Stinson; Larry L Bellinger; Yuan Peng; Phillip R Kramer
Journal:  Brain Res       Date:  2018-05-12       Impact factor: 3.252

3.  Association between Anterior Cingulate Neurochemical Concentration and Individual Differences in Hypnotizability.

Authors:  Danielle D DeSouza; Katy H Stimpson; Laima Baltusis; Matthew D Sacchet; Meng Gu; Ralph Hurd; Hua Wu; David C Yeomans; Nolan Willliams; David Spiegel
Journal:  Cereb Cortex       Date:  2020-05-18       Impact factor: 5.357

4.  Role for the Ventral Posterior Medial/Posterior Lateral Thalamus and Anterior Cingulate Cortex in Affective/Motivation Pain Induced by Varicella Zoster Virus.

Authors:  Phillip R Kramer; Jennifer Strand; Crystal Stinson; Larry L Bellinger; Paul R Kinchington; Michael B Yee; Mikhail Umorin; Yuan B Peng
Journal:  Front Integr Neurosci       Date:  2017-10-16

5.  Neurotransmitter alterations in the anterior cingulate cortex in Crohn's disease patients with abdominal pain: A preliminary MR spectroscopy study.

Authors:  Kun Lv; Wenwen Song; Rui Tang; Zhiyong Pan; Yong Zhang; Yi Xu; Bin Lv; Yihong Fan; Maosheng Xu
Journal:  Neuroimage Clin       Date:  2018-09-18       Impact factor: 4.881

6.  Pain-free resting-state functional brain connectivity predicts individual pain sensitivity.

Authors:  Tamas Spisak; Balint Kincses; Frederik Schlitt; Matthias Zunhammer; Tobias Schmidt-Wilcke; Zsigmond T Kincses; Ulrike Bingel
Journal:  Nat Commun       Date:  2020-01-10       Impact factor: 14.919

7.  Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study).

Authors:  Ariadna Colomer-Carbonell; Juan P Sanabria-Mazo; Halbert Hernández-Negrín; Xavier Borràs; Carlos Suso-Ribera; Azucena García-Palacios; Jordi Muchart; Josep Munuera; Francesco D'Amico; Michael Maes; Jarred W Younger; Albert Feliu-Soler; Antoni Rozadilla-Sacanell; Juan V Luciano
Journal:  BMJ Open       Date:  2022-01-06       Impact factor: 2.692

8.  Increased neural noise and impaired brain synchronization in fibromyalgia patients during cognitive interference.

Authors:  A J González-Villar; N Samartin-Veiga; M Arias; M T Carrillo-de-la-Peña
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

9.  Determining the association between fibromyalgia, the gut microbiome and its biomarkers: A systematic review.

Authors:  Sharon Erdrich; Jason A Hawrelak; Stephen P Myers; Joanna E Harnett
Journal:  BMC Musculoskelet Disord       Date:  2020-03-20       Impact factor: 2.362

10.  Metabolite activity in the anterior cingulate cortex during a painful stimulus using functional MRS.

Authors:  J Archibald; E L MacMillan; C Graf; P Kozlowski; C Laule; J L K Kramer
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.